- Report
- January 2026
- 180 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- November 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- October 2025
- 160 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2846EUR$3,250USD£2,471GBP
- Report
- May 2024
- 139 Pages
Global
From €3502EUR$3,999USD£3,040GBP
The Lenvima market is a subset of the larger thyroid cancer drug market. It is composed of drugs that target the VEGF-R3 receptor, which is a key factor in the development of thyroid cancer. Lenvima is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of the VEGF-R3 receptor, thus preventing the growth of cancer cells. Lenvima is approved for the treatment of advanced thyroid cancer in adults, and is also being studied for use in other types of cancer.
The Lenvima market is highly competitive, with several major pharmaceutical companies vying for market share. Companies such as Eisai, Merck, and Pfizer are all major players in the Lenvima market, offering their own versions of the drug. Other companies such as Novartis, AstraZeneca, and Bristol-Myers Squibb are also involved in the market, offering their own versions of the drug. Show Less Read more
